Publications by authors named "Maya Gottfried"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

38

Total Likes

99

Extended Reach

107,735

Social Features

39
D
DIO3 depletion attenuates ovarian cancer growth via reduced glycolysis and alterations in glutamine metabolism.
Dotan Moskovich, Daniel Beilinson, Amit Rosemarin, Aileen Cohen, Itai Fabian, Maya Gottfried

Mol Metab· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.
Aurelien Marabelle, David M O'Malley, Andrew E Hendifar, Paolo A Ascierto, Daniel Motola-Kuba, Maya Gottfried

Nat Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782.
Jair Bar, Emilio Esteban, Delvys Rodríguez-Abreu, Santiago Ponce Aix, Zsuzsanna Szalai, Maya Gottfried

Lung Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy.
Jair Bar, Raya Leibowitz, Niels Reinmuth, Astrid Ammendola, Eyal Jacob, Maya Gottfried

Front Immunol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC.
Hye Ryun Kim, Mark M Awad, Alejandro Navarro, Maya Gottfried, Solange Peters

JTO Clin Res Rep· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives.
Martin Reck, Sanjay Popat, Christian Grohé, Jesus Corral, Silvia Novello, Maya Gottfried

Lung Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.
Michele Maio, Mayur M Amonkar, Josephine M Norquist, Paolo A Ascierto, Ludmila Manzyuk, Maya Gottfried

Eur J Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.
Xiuning Le, Hiroshi Sakai, Enriqueta Felip, Remi Veillon, Marina Chiara Garassino, Maya Gottfried

Clin Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.
Mor Moskovitz, Elizabeth Dudnik, Sivan Shamai, Yakir Rotenberg, Noa Popovich-Hadari, Maya Gottfried

Oncologist· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncology Treatments during the COVID-19 Pandemic in Israel: the ONCOR Study.
Galit Hirsh-Yechezkel, Angela Chetrit, Sivan Ben Avraham, Abed Agbarya, Alexander Yakobson, Maya Gottfried

Isr Med Assoc J· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
Melissa L Johnson, Zanete Zvirbule, Konstantin Laktionov, Aslaug Helland, Byoung Chul Cho, Maya Gottfried

J Thorac Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study.
Daniel Reinhorn, Iryna Kuchuk, Tzippy Shochat, Bella Nisenbaum, Aaron Sulkes, Maya Gottfried

Breast Cancer Res Treat· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Maya Gottfried

J Clin Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies.
Antonio Passaro, Filippo de Marinis, Hai-Yan Tu, Konstantin K Laktionov, Jifeng Feng, Maya Gottfried

Front Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
Filippo de Marinis, Konstantin K Laktionov, Artem Poltoratskiy, Inna Egorova, Maximilian Hochmair, Maya Gottfried

Lung Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long term follow-up of EGFR mutated NSCLC cases.
Gad Rennert, Maya Gottfried, Hedy S Rennert, Flavio Lejbkowicz, Meira Frank

Transl Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rising Incidence of Lung Cancer in Arab Females, Jewish Females, and Arab Males from 1990 to 2014 in Israel.
Jair Bar, Marina Perelman, Damien Urban, Maya Gottfried, Mor Moskovitz

Isr Med Assoc J· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Charles M Rudin, Mark M Awad, Alejandro Navarro, Maya Gottfried, Solange Peters

J Clin Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
Sanjay Popat, Christian Grohé, Jesus Corral, Martin Reck, Silvia Novello, Maya Gottfried

Lung Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
Hyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, Jan H M Schellens, Steven Kao, Maya Gottfried

J Thorac Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niche origin of mesenchymal stem cells derived microvesicles determines opposing effects on NSCLC: Primary versus metastatic.
Oshrat Attar-Schneider, Mahmoud Dabbah, Liat Drucker, Maya Gottfried

Cell Signal· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Maya Gottfried

J Clin Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Maya Gottfried

J Clin Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of mesenchymal stem cells' secretome on lung cancer progression is contingent on their origin: primary or metastatic niche.
Oshrat Attar-Schneider, Liat Drucker, Maya Gottfried

Lab Invest· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis